GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (NAS:BPTH) » Definitions » ROE %
中文

Bio-Path Holdings (Bio-Path Holdings) ROE % : -909.51% (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Bio-Path Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Bio-Path Holdings's annualized net income for the quarter that ended in Dec. 2023 was $-13.49 Mil. Bio-Path Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $1.48 Mil. Therefore, Bio-Path Holdings's annualized ROE % for the quarter that ended in Dec. 2023 was -909.51%.

The historical rank and industry rank for Bio-Path Holdings's ROE % or its related term are showing as below:

BPTH' s ROE % Range Over the Past 10 Years
Min: -256.92   Med: -72.38   Max: -44.21
Current: -256.92

During the past 13 years, Bio-Path Holdings's highest ROE % was -44.21%. The lowest was -256.92%. And the median was -72.38%.

BPTH's ROE % is ranked worse than
90.82% of 1361 companies
in the Biotechnology industry
Industry Median: -44.08 vs BPTH: -256.92

Bio-Path Holdings ROE % Historical Data

The historical data trend for Bio-Path Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Path Holdings ROE % Chart

Bio-Path Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -77.11 -60.19 -51.52 -69.99 -220.02

Bio-Path Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -104.47 -181.19 -239.38 -338.16 -909.51

Competitive Comparison of Bio-Path Holdings's ROE %

For the Biotechnology subindustry, Bio-Path Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Path Holdings's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's ROE % falls into.



Bio-Path Holdings ROE % Calculation

Bio-Path Holdings's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-16.078/( (14.174+0.441)/ 2 )
=-16.078/7.3075
=-220.02 %

Bio-Path Holdings's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-13.488/( (2.525+0.441)/ 2 )
=-13.488/1.483
=-909.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Bio-Path Holdings  (NAS:BPTH) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-13.488/1.483
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-13.488 / 0)*(0 / 4.1205)*(4.1205 / 1.483)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*2.7785
=ROA %*Equity Multiplier
=N/A %*2.7785
=-909.51 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-13.488/1.483
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-13.488 / -13.488) * (-13.488 / -12.132) * (-12.132 / 0) * (0 / 4.1205) * (4.1205 / 1.483)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.1118 * N/A % * 0 * 2.7785
=-909.51 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Bio-Path Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Bio-Path Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Path Holdings (Bio-Path Holdings) Business Description

Traded in Other Exchanges
Address
4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.
Executives
Aline Sherwood director 347 BRANDYWINE DRIVE, IRWIN PA 15642
Tamaro Martina Molsbergen director 1307 SUMMERHILL DRIVE, MALVERN PA 19355
Mark P Colonnese director 4674 ANDREA POINTE, MARIETTA GA 30062
Peter Henry Nielsen director, officer: President, CEO & CFO 20651 PRINCE CREEK, KATY TX 77450
Paul Aubert director 4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE TX 77401
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Heath Cleaver director 4010 BALSAM FIR LN., SPRING TX 77386
Ulrich W. Mueller officer: COO & Secretary 17841 6TH AVE NW, SHORELINE WA 98177
Amy Sing director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Michael J. Garrison director 2626 SOUTH LOOP, SUITE 180, HOUSTON TX 77054
Douglas P Morris director 550 MADISON AVENUE, SUITE 3206, NEW YORK NY 10022
Gillian C Ivers-read director C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Thomas E Garrison director P O BOX 150248, OGDEN UT 84415